S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in

Kiniksa Pharmaceuticals Stock Forecast, Price & News

-0.25 (-1.20 %)
(As of 02/26/2021 12:00 AM ET)
Today's Range
Now: $20.57
50-Day Range
MA: $20.54
52-Week Range
Now: $20.57
Volume402,176 shs
Average Volume323,444 shs
Market Capitalization$1.40 billion
P/E RatioN/A
Dividend YieldN/A
Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and in Phase 1a clinical trial for the treatment of atopic dermatitis. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate investigational combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.
Kiniksa Pharmaceuticals logo


Notable Friday Option Activity: KNSA, OKTA, CZR
December 18, 2020 |  nasdaq.com
Is KNSA A Good Stock To Buy Now?
December 18, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:KNSA
Year FoundedN/A



Sales & Book Value

Annual SalesN/A
Book Value$4.10 per share


Net Income$-161,870,000.00


Market Cap$1.40 billion
Next Earnings Date4/27/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.68 out of 5 stars

Medical Sector

256th out of 1,960 stocks

Pharmaceutical Preparations Industry

122nd out of 771 stocks

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
-0.25 (-1.20 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KNSA News and Ratings via Email

Sign-up to receive the latest news and ratings for KNSA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Frequently Asked Questions

Is Kiniksa Pharmaceuticals a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Kiniksa Pharmaceuticals stock.
View analyst ratings for Kiniksa Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Kiniksa Pharmaceuticals?

Wall Street analysts have given Kiniksa Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Kiniksa Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Kiniksa Pharmaceuticals' next earnings date?

Kiniksa Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, April 27th 2021.
View our earnings forecast for Kiniksa Pharmaceuticals

How were Kiniksa Pharmaceuticals' earnings last quarter?

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) posted its quarterly earnings data on Tuesday, February, 23rd. The company reported ($0.79) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.64) by $0.15.
View Kiniksa Pharmaceuticals' earnings history

How has Kiniksa Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Kiniksa Pharmaceuticals' stock was trading at $16.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, KNSA shares have increased by 27.8% and is now trading at $20.57.
View which stocks have been most impacted by COVID-19

What price target have analysts set for KNSA?

4 equities research analysts have issued 12 month price targets for Kiniksa Pharmaceuticals' stock. Their forecasts range from $24.00 to $40.00. On average, they anticipate Kiniksa Pharmaceuticals' share price to reach $33.75 in the next twelve months. This suggests a possible upside of 64.1% from the stock's current price.
View analysts' price targets for Kiniksa Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Kiniksa Pharmaceuticals' key executives?

Kiniksa Pharmaceuticals' management team includes the following people:
  • Mr. Sanj K. Patel, CEO & Chairman (Age 51, Pay $1.25M)
  • Dr. John F. Paolini, Chief Medical Officer (Age 56, Pay $593.88k)
  • Mr. Mark Ragosa C.F.A., Interim CFO and VP of Investor Relations & Fin. (Age 47)
  • Mr. Thomas W. Beetham, Exec. VP of Corp. Devel. & Operations, Chief Legal Officer and Sec. (Age 51)
  • Mr. Michael R. Megna, Chief Accounting Officer & VP of Fin. (Age 50)
  • Mr. Dave Nichols, Sr. VP of Technical Operations
  • Ms. Annalisa D'Andrea, Chief Scientific Officer
  • Ms. Melissa Manno, Sr. VP of HR
  • Mr. Rasmus Holm-Jorgensen, Sr. VP, Chief Strategy & Portfolio Officer
  • Mr. Carsten Boess, Exec. VP of Corp. Affairs (Age 54)

What is Sanj K. Patel's approval rating as Kiniksa Pharmaceuticals' CEO?

1 employees have rated Kiniksa Pharmaceuticals CEO Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among Kiniksa Pharmaceuticals' employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Kiniksa Pharmaceuticals' key competitors?

What other stocks do shareholders of Kiniksa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Dicerna Pharmaceuticals (DRNA), Vaxart (VXRT) and Advanced Micro Devices (AMD).

When did Kiniksa Pharmaceuticals IPO?

(KNSA) raised $126 million in an initial public offering on Thursday, May 24th 2018. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Kiniksa Pharmaceuticals' stock symbol?

Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."

Who are Kiniksa Pharmaceuticals' major shareholders?

Kiniksa Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.22%), Janus Henderson Group PLC (1.66%), Avidity Partners Management LP (1.42%), Barclays PLC (1.00%), Rice Hall James & Associates LLC (0.88%) and Nuveen Asset Management LLC (0.63%). Company insiders that own Kiniksa Pharmaceuticals stock include John F Paolini, Sanj K Patel and Thomas W Beetham.
View institutional ownership trends for Kiniksa Pharmaceuticals

Which major investors are selling Kiniksa Pharmaceuticals stock?

KNSA stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Opaleye Management Inc., Strs Ohio, Landscape Capital Management L.L.C., Nuveen Asset Management LLC, Alyeska Investment Group L.P., Alyeska Investment Group L.P., and Northern Trust Corp. Company insiders that have sold Kiniksa Pharmaceuticals company stock in the last year include Sanj K Patel, and Thomas W Beetham.
View insider buying and selling activity for Kiniksa Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Kiniksa Pharmaceuticals stock?

KNSA stock was purchased by a variety of institutional investors in the last quarter, including Avidity Partners Management LP, Rice Hall James & Associates LLC, Barclays PLC, BlackRock Inc., Bank of New York Mellon Corp, Credit Suisse AG, Wells Fargo & Company MN, and Morgan Stanley.
View insider buying and selling activity for Kiniksa Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Kiniksa Pharmaceuticals?

Shares of KNSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kiniksa Pharmaceuticals' stock price today?

One share of KNSA stock can currently be purchased for approximately $20.57.

How much money does Kiniksa Pharmaceuticals make?

Kiniksa Pharmaceuticals has a market capitalization of $1.40 billion. The company earns $-161,870,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis.

How many employees does Kiniksa Pharmaceuticals have?

Kiniksa Pharmaceuticals employs 135 workers across the globe.

What is Kiniksa Pharmaceuticals' official website?

The official website for Kiniksa Pharmaceuticals is www.kiniksa.com.

Where are Kiniksa Pharmaceuticals' headquarters?

Kiniksa Pharmaceuticals is headquartered at CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11.

How can I contact Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The company can be reached via phone at 44-80-8189-6257 or via email at [email protected]

This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.